For example, by pre-testing tumor samples for specific phenotypes and functional states of immune cells, doctors can predict the patient’s responsiveness to PD-1/PD-L1 or CTLA-4 inhibitors, thus selectively choosing the treatment method most likely to benefit (67). This evidence concerns the gene CTLA4 and neoplasm.